Literature DB >> 22364315

Tumor accumulation, penetration, and antitumor response of cisplatin-loaded gelatin/poly(acrylic acid) nanoparticles.

Dan Ding1, Jing Wang, Zhenshu Zhu, Rutian Li, Wei Wu, Baorui Liu, Xiqun Jiang.   

Abstract

In this report, the cisplatin (CDDP)-loaded gelatin/poly(acrylic acid) (GEL-PAA) nanoparticles with a spherical shape and drug loading content of 24.6% were prepared. In vivo near-infrared fluorescence (NIRF) imaging and ex vivo gamma scintillation counting analyses reveal that CDDP-loaded GEL-PAA nanoparticles have prominent passive tumor-targeting ability and the nontarget nanoparticles can be readily excreted from the body. Further, it is demonstrated that the CDDP-loaded nanoparticles have the ability to penetrate the tumor after their extravasation through the leaky vessels and distribute in a distance of about 20 μm from the vessels at 24 h postinjection. The in vivo antitumor responses reveal that the nanoparticle formulation exhibits significantly superior in vivo antitumor effect than free CDDP by the comparison of tumor volume and the examinations of cell apoptosis and proliferation in tumor tissues through proliferating cell nuclear antigen (PCNA) and terminal deoxynucleotidyl-transferase-mediated nick end labeling (TUNEL) methods.
© 2012 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22364315     DOI: 10.1021/am300138z

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  9 in total

1.  In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma.

Authors:  YanXin Yu; Shan Xu; Hong You; YinJie Zhang; Bo Yang; XiaoYang Sun; LingLin Yang; Yue Chen; ShaoZhi Fu; JingBo Wu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

2.  An efficient Trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-poly(ε-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion.

Authors:  Huae Xu; Zhibo Hou; Hao Zhang; Hui Kong; Xiaolin Li; Hong Wang; Weiping Xie
Journal:  Int J Nanomedicine       Date:  2013-12-27

3.  Efficient delivery of ursolic acid by poly(N-vinylpyrrolidone)-block-poly (ε-caprolactone) nanoparticles for inhibiting the growth of hepatocellular carcinoma in vitro and in vivo.

Authors:  Hao Zhang; Donghui Zheng; Jing Ding; Huae Xu; Xiaolin Li; Weihao Sun
Journal:  Int J Nanomedicine       Date:  2015-03-11

Review 4.  Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy.

Authors:  Albert Yu; Xiaoyong Dai; Zixian Wang; Huaqing Chen; Bing Guo; Laiqiang Huang
Journal:  Biosensors (Basel)       Date:  2022-02-10

Review 5.  Exploiting a New Approach to Destroy the Barrier of Tumor Microenvironment: Nano-Architecture Delivery Systems.

Authors:  Yanting Sun; Yuling Li; Shuo Shi; Chunyan Dong
Journal:  Molecules       Date:  2021-05-05       Impact factor: 4.411

6.  Efficient antitumor effect of co-drug-loaded nanoparticles with gelatin hydrogel by local implantation.

Authors:  Hao Zhang; Yong Tian; Zhenshu Zhu; Huae Xu; Xiaolin Li; Donghui Zheng; Weihao Sun
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

7.  Mathematical Based Calculation of Drug Penetration Depth in Solid Tumors.

Authors:  Hamidreza Namazi; Vladimir V Kulish; Albert Wong; Sina Nazeri
Journal:  Biomed Res Int       Date:  2016-06-08       Impact factor: 3.411

Review 8.  Polymeric nanocarriers as stimuli-responsive systems for targeted tumor (cancer) therapy: Recent advances in drug delivery.

Authors:  Mosa Alsehli
Journal:  Saudi Pharm J       Date:  2020-01-24       Impact factor: 4.330

9.  Furin-responsive triterpenine-based liposomal complex enhances anticervical cancer therapy through size modulation.

Authors:  Yunyan Chen; Mengfei Guo; Ding Qu; Yuping Liu; Jian Guo; Yan Chen
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.